Skip to main content
OpenTrials

Clinical trial condition

Prurigo Nodularis

Explore clinical trials studying Prurigo Nodularis. Study availability and eligibility vary by location and protocol.

35 public trials 7 recruiting studies
Refine in advanced search Browse all conditions

Prurigo Nodularis trial results

Recruiting

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

NCT06988618

Conditions
Prurigo Nodularis
Locations
  • Galderma Investigational Site # 8893 Birmingham, Alabama, United States
  • Galderma Investigational Site # 7077 Phoenix, Arizona, United States
  • Galderma Investigational Site # 7060 Phoenix, Arizona, United States
  • Galderma Investigational Site # 7067 Tucson, Arizona, United States
View all 51 locations
View Trial Details
Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

NCT06293053

Conditions
Prurigo Nodularis
Locations
  • Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400021 Palo Alto, California, United States
  • Mission Dermatology Center- Site Number : 8400011 Rancho Santa Margarita, California, United States
  • Pediatric Center of Excellence (PCE) - Miami Pediatric Endocrinology- Site Number : 8400005 Coral Gables, Florida, United States
  • Life Clinical Trials - Coral Springs- Site Number : 8400018 Coral Springs, Florida, United States
View all 14 locations
View Trial Details
Recruiting

A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine

NCT06087627

Conditions
Prurigo Nodularis
Locations
  • Investigational Site Number: 013 Adernach, Germany
  • Investigational site number: 001 Berlin, Germany
  • Investigational Site Number: 002 Berlin, Germany
  • Investigational Site Number: 023 Chemnitz, Germany
View Trial Details
Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Conditions
Atopic Dermatitis, Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +15 more
Locations
  • Innovate Clinical Research Waitara, New South Wales, Australia
  • Cmax Clinical Research Adelaide, South Australia, Australia
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing Municipality, China
View all 13 locations
View Trial Details
Completed

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

NCT03816891

Conditions
Pathological Conditions, Signs and Symptoms, Prurigo Nodularis, Pruritis, +5 more
Locations
  • Arizona Research Center Phoenix, Arizona, United States
  • Investigate MD, LLC Scottsdale, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • First OC Dermatology Fountain Valley, California, United States
View all 86 locations
View Trial Details

Related conditions